|
|
1. Ⅰ~Ⅲ期 LCNEC 患者
手术切除是早期 LCNEC 患者的主要治疗手段。但没有证据表明手术方式和术后整体生存率有明显关系［28］。多项回顾性分析显示，完全切除的Ⅰ期 LCNEC 患者，术后接受以铂类为基础两药方案的辅助化疗比单纯手术治疗生存获益更显著［29-30］。尽管缺乏随机Ⅲ期临床研究，目前的研究结果强调了早期 LCNEC 综合治疗的重要性，以铂类为基础的化疗方案是早期患者辅助治疗的首选［31］。胸部放疗或预防性脑照射的作用目前仍不清楚，没有证据表明放疗能使 LCNEC患者获益［32］。
2. 进展期及晚期 LCNEC 患者
这类患者治疗策略的选择仍存在争议。一项纳入 5 797 例局部晚期 LCNEC 患者的回顾性研究显示，根治性同步放化疗较单纯化疗效果更佳［33］。美国临床肿瘤学会同时推荐 SCLC 与 NSCLC 的治疗方案用于 LCNEC，但最近一项基于基因组研究结果表明，RB1 野生型和 / 或表达 RB1 蛋白的 LCNEC 按 NSCLC 化疗方案治疗，OS 明显优于 SCLC 化疗方案［34］。
3. 晚期 LCNEC 免疫治疗
一项回顾性研究显示，纳武利尤单抗或帕博利珠单抗治疗经治晚期 LCNEC 患者，60% 患者疗效为 PR，10% 患者疗效为 SD，PFS 为 57 周，患者耐受性好［35］。有研究报道了帕博利珠单抗治疗一例 PD-L1 表达阴性的 LCNEC 患者，疗效显著，提示即使 PD-L1 表达阴性，免疫检查点抑制剂对转移性 LCNEC 患者仍可能为一种有效的治疗选择［36］。
参考指南：
中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会 (CSCO) 小细胞肺癌诊疗指南2024.人民卫生出版社.北京 2024
中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会 (CSCO) 神经内分泌肿瘤诊疗指南2022.人民卫生出版社.北京 2022
参考文献
［1］ HONG CR, WIRTH LJ, NISHINO M, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer, 2014, 86 (2): 241-246.
［2］ WIRTH LJ, CARTER MR, JÄNNE PA, et al. Outcome of patients with pulmonary carcinoid tumors receiving chemo- therapy or chemoradiotherapy. Lung Cancer, 2004, 44 (2): 213-220.
［3］ FILOSSO PL, YAO X, AHMAD U, et al. Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg, 2015, 149 (1): 103-109.
［4］ RIMNER A, YAO X, HUANG J, et al. Postoperative radiation therapy is associated with longeroverall survival in completely resected stage Ⅱ and Ⅲ thymoma-an analysis of the international thymic malignancies interest group ret- rospective database. J Thorac Oncol, 2016, 11 (10): 1785-1792.
［5］ BIAN D, QI M, HU J, et al. The comparison of predictive factors regarding prognoses and invasion of thymic neuro- endocrine tumors preoperatively and postoperatively. J Thorac Dis, 2018, 10 (3): 1657-1669.
［6］ CRONA J, FANOLA I, LINDHOLM DP, et al. Effect of temozolomide in patients with metastatic bronchial carci- noids. Neuroendocrinology, 2013, 98 (2): 151-155.
［7］ PAULSON AS, BERGSLAND EK. Systemic therapy for advanced carcinoid tumors: Where do we go from here?. J Natl Compr Canc Netw, 2012, 10 (6): 785-793.
［8］ MEDLEY L, MOREL AN, FARRUGIA D, et al. Phase Ⅱ study of single agent capecitabine in the treatment of meta- static non-pancreatic neuroendocrine tumours. Br J Cancer, 2011, 104 (7): 1067-1070.
［9］ BAJETTA E, CATENA L, PROCOPIO G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for pro- gressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol, 2007, 59 (5): 637-642.
［10］ EKEBLAD S, SUNDIN A, JANSON ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res, 2007, 13 (10): 2986-2991.
［11］ CRONA J, FANOLA I, LINDHOLM DP, et al. Effect of temozolomide in patients with metastatic bronchial carci- noids. Neuroendocrinology, 2013, 98 (2): 151-155.
［12］ YAO JC, PHAN AT, CHANG DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase Ⅱ study. J Clin Oncol, 2008, 26 (26): 4311-4318.
［13］ PAVEL ME, HAINSWORTH JD, BAUDIN E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet, 2011, 378 (9808): 2005-2012.
［14］ YAO JC, FAZIO N, SINGH S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lan- cet, 2016, 387 (10022): 968-977.
［15］ FAZIO N, BUZZONI R, DELLE FAVE G, et al. Everolimus in advanced, progressive, well-differentiated, non- functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci, 2018, 109 (1): 174-181.
［16］ IMHOF A, BRUNNER P, MARINCEK N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol, 2011, 29 (17): 2416-2423.
［17］ KRENNING EP, TEUNISSEN JJ, VALKEMA R, et al. Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors. J Endocrinol Invest, 2005, 28 (11 Suppl International): 146-150.
［18］ KWEKKEBOOM DJ, BAKKER WH, KAM BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA (0), Tyr3] octreotate. Eur J Nucl Med Mol Imaging, 2003, 30 (3): 417-422.
［19］ KWEKKEBOOM DJ, TEUNISSEN JJ, BAKKER WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol, 2005, 23 (12): 2754-2762.
［20］ KWEKKEBOOM DJ, TEUNISSEN JJ, KAM BL, et al. Treatment of patients who have endocrine gastroenteropan- creatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am, 2007, 21 (3): 561-573.
［21］ BUSHNELL DL JR, O′DORISIO TM, O′DORISIO MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol, 2010, 28 (10): 1652-1659.
［22］ KONG G, THOMPSON M, COLLINS M, et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging, 2014, 41 (10): 1831-1844.
［23］ VILLARD L, ROMER A, MARINCEK N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90) Y-DOTA]-TOC versus [(90) Y-DOTA]-TOC plus [(177) Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol, 2012, 30 (10): 1100-1106.
［24］ HÖRSCH D, EZZIDDIN S, HAUG A, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: First results of a multi-institutional cancer registry. Recent Results Cancer Res, 2013, 194: 457-465.
［25］ BRABANDER T, VAN DER ZWAN WA, TEUNISSEN J, et al. Long-term efficacy, survival, and safety of [177Lu- DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res, 2017, 23 (16): 4617-4624.
［26］ U. S. Food and Drug Administration. FDA approves new treatment for certain digestive tract cancers. Silver Springs, MD: U. S. Food and Drug Administration.(2018-01-16)[2024-03-25]. https://www. fda. gov/news-events/press- announcements/fda-approves-new-treatment-certain-digestive-tract-cancers.
［27］ CAPDEVILA J, HERNANDO J, TEULE A, et al. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nature Communications, 2023, 14: 2973.
［28］ GRAND B, CAZES A, MORDANT P, et al. High grade neuroendocrine lung tumors: Pathological characteristics, surgical management and prognostic implications. Lung Cancer, 2013, 81 (3): 404-409.
［29］ SAJI H, TSUBOI M, MATSUBAYASHI J, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs, 2010, 21 (1): 89-93.
［30］ KENMOTSU H, NIHO S, ITO T, et al. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Lung Cancer, 2014, 84 (3): 254-258.
［31］ GRIDELLI C, ROSSI A, AIROMA G, et al. Treatment of pulmonary neuroendocrine tumours: State of the art and future developments. Cancer Treat Rev, 2013, 39 (5): 466-472.
［32］ LO RUSSO G, PUSCEDDU S, PROTO C, et al. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol, 2016, 37 (6): 7047-7057.
［33］ LIMONNIK V, ABEL S, FINLEY GG, et al. Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analy- sis. Lung Cancer, 2020, 150: 107-113.
［34］ DERKS JL, LEBLAY N, THUNNISSEN E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carci- noma predict chemotherapy treatment outcome. Clin Cancer Res, 2018, 24 (1): 33-42.
［35］ LEVRA MG, MAZIERES J, VALETTE CA, et al. P1. 07-012 efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: Results from a french retrospective cohort. Topic: drug treatment alone and in combina- tion with radiotherapy. J Thoracic Oncol, 2017, 12 (1): S702-S703.
［36］ WANG VE, URISMAN A, ALBACKER L, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer, 2017, 5 (1): 75.
|
|
